|

ROCKET LAB USA INC (RKLB)

US7731221062 - Common Stock

4.8  +0.1 (+2.13%)

After market: 4.81 +0.01 (+0.21%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to RKLB. RKLB was compared to 64 industry peers in the Aerospace & Defense industry. Both the profitability and financial health of RKLB have multiple concerns. RKLB is valued quite expensively, but it does show have an excellent growth rating.



0

1. Profitability

1.1 Basic Checks

In the past year RKLB has reported negative net income.
RKLB had a negative operating cash flow in the past year.

1.2 Ratios

With a Return On Assets value of -17.81%, RKLB is not doing good in the industry: 73.02% of the companies in the same industry are doing better.
RKLB's Return On Equity of -28.90% is on the low side compared to the rest of the industry. RKLB is outperformed by 63.49% of its industry peers.
Industry RankSector Rank
ROA -17.81%
ROE -28.9%
ROIC N/A
ROA(3y)-18.32%
ROA(5y)N/A
ROE(3y)-29.26%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 15.97%, RKLB is doing worse than 68.25% of the companies in the same industry.
RKLB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 15.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

3

2. Health

2.1 Basic Checks

RKLB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RKLB has been increased compared to 1 year ago.
RKLB has a worse debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 2.92 indicates that RKLB is not a great score, but indicates only limited risk for bankruptcy at the moment.
RKLB has a Altman-Z score of 2.92. This is in the better half of the industry: RKLB outperforms 61.90% of its industry peers.
RKLB has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
RKLB has a better Debt to Equity ratio (0.03) than 85.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 2.92
ROIC/WACCN/A
WACC9.72%

2.3 Liquidity

RKLB has a Current Ratio of 1.67. This is a normal value and indicates that RKLB is financially healthy and should not expect problems in meeting its short term obligations.
RKLB has a Current ratio (1.67) which is comparable to the rest of the industry.
RKLB has a Quick Ratio of 1.33. This is a normal value and indicates that RKLB is financially healthy and should not expect problems in meeting its short term obligations.
RKLB has a Quick ratio (1.33) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.67
Quick Ratio 1.33

7

3. Growth

3.1 Past

RKLB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -80.00%.
The Revenue has grown by 26.60% in the past year. This is a very strong growth!
Measured over the past years, RKLB shows a very strong growth in Revenue. The Revenue has been growing by 63.36% on average per year.
EPS 1Y (TTM)-80%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-14.29%
Revenue 1Y (TTM)26.6%
Revenue growth 3Y63.36%
Revenue growth 5YN/A
Revenue growth Q2Q7.29%

3.2 Future

RKLB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 33.78% yearly.
Based on estimates for the next years, RKLB will show a very strong growth in Revenue. The Revenue will grow by 46.60% on average per year.
EPS Next Y-50.96%
EPS Next 2Y-9.4%
EPS Next 3Y24.55%
EPS Next 5Y33.78%
Revenue Next Year20.9%
Revenue Next 2Y43.46%
Revenue Next 3Y44.81%
Revenue Next 5Y46.6%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

1

4. Valuation

4.1 Price/Earnings Ratio

RKLB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RKLB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as RKLB's earnings are expected to grow with 24.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.4%
EPS Next 3Y24.55%

0

5. Dividend

5.1 Amount

RKLB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ROCKET LAB USA INC

NASDAQ:RKLB (12/8/2023, 7:13:42 PM)

After market: 4.81 +0.01 (+0.21%)

4.8

+0.1 (+2.13%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryAerospace & Defense
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.33B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.81%
ROE -28.9%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 15.97%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.67
Quick Ratio 1.33
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-80%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-50.96%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)26.6%
Revenue growth 3Y63.36%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y